Growth Opportunities and Trends in the Zika Virus Therapeutics Market: Key Insights for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the market size evolved in recent years?
The therapeutics market for the zika virus has seen robust expansion lately. The market is projected to escalate from $30.22 billion in 2024 to $32.16 billion in 2025, with a compound annual growth rate (CAGR) pegged at 6.4%. The significant growth during the historical period can be credited to a surge in infection rates, the impact of comorbidities associated with zika virus infection, an increased call for preventative actions, the mounting significance of public health programs, and the broadening of worldwide health campaigns.
What are the predictions for the market size in the coming years?
Expectations are for the zika virus therapeutics market to exhibit robust growth in the coming years, reaching a value of $40.64 billion by 2029 with a CAGR of 6.0%. This projected growth can be credited to several factors such as an increased focus on clinical trials, surge in therapeutic demand from zika prevalent areas, investment acceleration in R&D, the access to serology kits for quality diagnosis, and a spike in substitute programs. The forecast period is likely to see a series of trends including advances in antiviral medicine development, the evolution of serological tests, cutting-edge innovations in monoclonal antibody techniques, introduction of novel therapies, and progress in rapid diagnostic technology.
Get your market report here!
https://www.thebusinessresearchcompany.com/report/zika-virus-therapeutics-global-market-report
What main drivers are fueling expansion in the market?
The surge in infection rates is predicted to boost the expansion of the Zika virus therapeutics market in the future. An infection rate measures the likelihood or hazard of an infection taking place within a specific group over a set timeframe. The infection incidence arises from factors such as poor vector control, environmental conditions conducive to mosquito breeding, and restricted access to preventive healthcare in the regions impacted. This requires robust Zika virus therapeutics, thus stimulating the creation and funding of vaccines and treatments to tackle the escalating public health menace. As an illustration, the UK Health Security Agency, a UK governmental organization, reported around eight confirmed cases of the Zika virus from January to June 2024 in December of that year, marking a 700% surge in incidence compared to the corresponding period in 2023. Consequently, the increasing infection incidence rate will fuel the growth of the Zika virus therapeutics market.
How is the global market divided into key segments?
The zika virus therapeutics market covered in this report is segmented –
1) By Product: Acetaminophen, Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Vaccine Type: Inactivated Vaccine, Subunit Vaccine, Live-Attenuated Vaccine, Other Vaccine Types
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Acetaminophen: Oral Tablets, Oral Suspensions, Intravenous Formulations
2) By Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Celecoxib
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21323&type=smp
Who are the key firms paving the way for growth in the market?
Major companies operating in the zika virus therapeutics market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Moderna Inc., DiaSorin S.p.A., Emergent BioSolutions Inc., ARUP Laboratories, Valneva SE, Bharat Biotech International Limited, Euroimmun AG, Tiangen Biotech Co. Ltd., Creative Diagnostics, Inovio Pharmaceuticals Inc., GeoVax Labs Inc., Moleculin Biotech Inc., BioVaxys Technology Corp., Kimer Med Limited, LumiQuick Diagnostics Inc.
What are the key trends shaping the future of the market?
Leading corporations in the zika virus therapeutics market are concentrated on advancing innovative technologies. They are specifically trying to develop second-generation adjuvanted inactivated vaccines that can augment the immune response, augment vaccine efficiency, and offer extended protection from the virus. A second-generation adjuvanted inactivated vaccine is a vaccine that merges an inactivated virus with an immune-strengthening adjuvant to improve the body’s immune response and thus offer stronger protection against the intended disease. For example, in March 2024, Valneva SE, a biotechnology firm based in France that specializes in vaccine production, declared the onset of Phase 1 clinical tests for VLA1601. This is a highly purified inactivated vaccine contender against the Zika virus (ZIKV), created using the same manufacturing method as Valneva’s licensed Japanese encephalitis vaccine, IXIARO. The vaccine is adjuvanted, involving substances that heighten the immune response, a critical aspect to its efficacy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21323
What regions are contributing significantly to the growth of the market?
North America was the largest region in the zika virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zika virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Antibody Contract Manufacturing Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
Antibody Drug Conjugates Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
